VEGFA and age-related macular degeneration: We employed ranibizumab, a monoclonal antibody to VEGF that has recently been approved by the FDA to treat wet AMD and DME, and a shRNA specifically against CTGF mRNA to inhibit VEGF signaling and CTGF expression, respectively.